Gastric ulcerogenic and healing impairment effects of risedronate, a nitrogen-containing bisphosphonate in rats. Comparison with alendronate and minodronate

Journal of Physiology and Pharmacology

Volumn 62, Issue 6, 2011, Pages 609-618

  Amagase, K ^a   Inaba, A ^a   Senta, T ^a   Ishikawa, Y ^a   Nukui, K ^a   Murakami, T ^a   Takeuchi, K ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Alendronate; Bisphosphonate; Gastric ulcers; Lipid peroxidatio; Minodronate; Mucosal irritation; Risedronate; Stomach; Superoxide dismutase

Indexed keywords

ALENDRONIC ACID; FIBROBLAST GROWTH FACTOR 2; GLUTATHIONE; MINODRONIC ACID; MYELOPEROXIDASE; RISEDRONIC ACID; SUPEROXIDE DISMUTASE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; HEALING IMPAIRMENT; LIPID PEROXIDATION; MALE; MUCOSA INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; STOMACH MUCOSA; STOMACH ULCER; UPREGULATION;

ALENDRONATE; ANIMALS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ETIDRONIC ACID; IMIDAZOLES; MALE; NITROGEN; RATS; RATS, SPRAGUE-DAWLEY; STOMACH ULCER; WOUND HEALING;

EID: 84856935527     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Geddes AD, D'Souza SM, Ebetino FH, Ibotson KJ. Bisphosphonates: structure- activity relationship and therapeutic implications. Bone Miner Res 1994; 8: 265-365.
2. Lin JH, Duggan DE, Chen I, Ellsworth RE. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 1991; 19: 297-300.
3. Graham D Y. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 2002; 47: 1665-1678.
4. Marshall JK, Rainsford KD, James C, Hunt RH. A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract. Aliment Pharmacol Ther 2000; 14: 1451-1457.
5. Lowe CE, Depew TW, Vanner SJ, Paterson WG, Meddings JB. Upper gastrointestinal toxicity of alendronate. Am J Gastroenterol 2000; 95: 634-640.
6. Blank MA, Ems BL, Gibson GW, et al. Nonclinical model for assessing gastric effects of bisphosphonates. Dig Dis Sci 1997; 42: 281-288.
7. Wallace JL, Dicay M, McKnight W, Bastaki S, Blank MA. N-bisphosphonates cause gastric epithelial injury independent of effects on the microcirculation. Aliment Pharmacol Ther 1999; 13: 1675-1682.
8. Kanatsu K, Aihara E, Okayama M, Kato S, Takeuchi K. Mucosal irritative and healing impairment action of risedronate in rat stomachs: comparison with alendronate. J Gastroenterol Hepatol 2004; 19: 512-520.
9. Ohashi Y, Aihara E, Takasuka H, Takahashi K, Takeuchi K. Antral ulcers induced by alendronate, a nitrogen-containing bisphosphonate, in rat stomachs: prophylactic effect of rebamipide. J Physiol Pharmacol 2009; 60: 85-93.
10. Elliott SN, McKnight W, Davies NM, MacNaughton WK. Wallace JL. Alendronate induces gastric injury and delays ulcer healing in rodents. Life Sci 1998; 62: 77-91.
11. Amagase K, Hayashi S, Nishikawa K, Aihara E, Takeuchi K. Impairment of gastric ulcer healing by alendronate, a nitrogen-containing bisphosphonate, in rats. Dig Dis Sci 2007; 52: 1879-1889.
12. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vbertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis 2000; 11: 83-91.
13. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster J Y. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2000; 85: 1895-1900.
14. Lanza FL, Hunt RH, Thomason AB, Provenza JM, Blank MA. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119: 631-638.
15. Castro GA, Roy SA, Stockstill RD. Trichinella spiralis. Peroxidase activity in isolated cells from the rat intestine. Exp Parasitol 1974; 36: 307-315.
16. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thio-barbituric acid reaction. Anal Biochem 1979; 95: 351-358.
17. Ikeda H, Kawana D, Maeda S, Sawamura M. Spectrophotometric assay for superoxide dismutasebased on the reduction of highly water-soluble tetrazolium salts by xanthine-xanthine oxidase. Biosci Biotechnol Biochem 1999; 63: 485-488.
18. Kaplowitz N, Kuhenkamp J, Goldstein JL, Reeve J. Effect of salicylates and phenobarbital on hepatic glutathione in the rats. J Pharmacol Exp Ther 1980; 212: 240-245.
19. Takeuchi K, Okada M, Niida H, Okabe S. Role of sulfhydryls in mucosal injury caused by ethanol: relation to microvascular permeability, gastric motility and cytoprotection. J Pharmacol Exp Ther 1989; 248: 836-841.
20. Hatazawa R, Tanaka A, Tanigami M, et al. Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors. Am J Physiol 2007; 293: G788-G797.
21. Laemmli UK. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
22. Takeuchi K, Kato S, Amagase K. Gastric ulcerogenic and healing impairment actions of alendronate, a nitrogen-containing bisphosphonate: prophylactic effects of rebamipide. Curr Pharm Des 2011; 17: 1602-1611.
23. Lichtenberger LM, Romeo JJ, Gibson GW, Blank MA. Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 2000; 45: 1792-1801.
24. Nozaki K, Mori M, Shibazaki K, et al. Safety pharmacology studies of minodronic acid. Clin Pharmacol Ther 2008; 18: S99-S128.
25. Satoh H, Guth PH. Role of gastric acid and prostaglandins in the formation of gastric antral ulcers produced by indomethacin in the rat. Prostaglandins 1981; 21(Suppl): 131-137.
26. Satoh H, Guth PH, Grossman MI. Role of food in gastrointestinal ulceration produced by indomethacin in the rat. Gastroenterology 1982; 83: 210-215.
27. Yamamoto O, Okada M, Okabe S. Effects of a proton pump inhibitor, omeprazole, on gastric secretion and gastric and duodenal ulcers or erosions in rats. Dig Dis Sci 1984; 29: 394-401.
28. Miller TA. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol 1983; 245: G601-G623.
29. Takeeda M, Hayashi Y, Yamato M, Murakami M, Takeuchi K. Roles of endogenous prostaglandins and cyclooxygenase isozymes in mucosal defense of inflamed rat stomach. J Physiol Pharmacol 2003; 55: 193-205.
30. Chen SH, Pan S, Okita K, Takemoto T. Role of superoxide dismutase in mechanism of diethyldithiocarbamate-induced gastric antral ulcer in rats: protective effect of prostaglandin, cimetidine and pirenzepine. J Gastroenterol Hepatol 1993; 8: 457-461.
31. Ogino K, Hobara T, Ishiyama H, et al. Antiulcer mechanism of action of rebamipide, a novel antiulcer compound, on diethyldithiocarbamate-induced antral gastric ulcers in rats. Eur J Pharmacol 1992; 212: 9-13.
32. Perry MA, Wadhwa S, Parks DA, Pickard W, Granger DN. Role of oxygen radicals in ischemia-induced leasions in the cat stomach. Gastroenterology 1986; 90: 362-367.
33. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112: 387-397.
34. Brzozowski T, Konturek PC, Konturek SJ. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech 2001; 53: 343-53.
35. Hatazawa R, Tanaka A, Tanigami M, et al. Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors. Am J Physiol 2007; 293: G788-G797.
36. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zolendronic acid. J Pharmacol Exp Ther 2002; 302: 1055-1061.
37. Tarnawski AS, Jones MK. The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: involvement of EGF-R signal transduction pathways. J Clin Gastroenterol 1998; 27: S12-S20.
38. Bornfeldt KE, Raines EW, Graves LM, Skinner MP, Krebs E G, Ross R. Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Ann NY Acad Sci 1995; 766: 416-430.
39. Szabo S, Vincze A, Sandor ZS, Gombos Z. Vascular approach to gastroduodenal ulceration: new studies with endothelins and VEGF. Dig Dis Sci 1998; 43: 40S-45S.
40. Ernst H, Konturek PC, Hahn EG, Stosiek HP, Brzozowski T, Konturek SJ. Effect of local injection with basic fibroblast growth factor (bFGF) and neutralizing antibody to bFGF on gastric ulcer healing, gastric secretion, angiogenesis and gastric blood flow. J Physiol Pharmacol 2001; 52: 377-390.
41. Russell RG. Bisphosphonates: the first 40 years. Bone 2011; 49: 2-19.